Brensocatib significantly reduced the rate of pulmonary exacerbations and slowed lung function decline in patients with ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Incorporated announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic ...